Evercore ISI initiated coverage of Mind Medicine (MNMD) with an Outperform rating and $23 price target Mind Medicine, which is developing a novel oral formulation of LSD, has two lead indications – generalized anxiety disorder and major depressive disorder – plus there are multiple large expansion opportunities, notes the analyst, who increasingly believes that psychedelics will play a role in future treatment paradigms.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNMD: